The Contrast Media Wars Get Hot
Executive Summary
AmeriNet officials were upset that Mallinckrodt was unwilling to offer AmeriNet the same terms it had Premier. When Mallinckrodt said "no", AmeriNet turned to Bracco.
You may also be interested in...
Amersham's Push for High-Value Diagnostics
Amersham Health is applying Big Pharma marketing and R&D strategies to the traditionally stodgy, highly price-sensitive field of diagnostic imaging contrast agents. It has been far more aggressive than competitors in working to make innovation the basis of competition. But some analysts question whether the company can maintain near-to-mid-term growth as it awaits results of its risky, long-term effort in molecular imaging.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.